Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Fineline Cube Jul 16, 2026
Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Company Deals

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Fineline Cube Jul 16, 2026
Company Deals

Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics

Fineline Cube Jul 15, 2026
Company Deals

Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger

Fineline Cube Jul 15, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor

Fineline Cube Jul 16, 2026
Company Drug

Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B

Fineline Cube Jul 16, 2026
Company Deals

TÜV Partners with Lancy Co., Ltd’s BRAVOU to Enhance Medical Aesthetics Services in China

Fineline Cube May 31, 2024

Technischer Überwachungs-Verein (TÜV), a Germany-based international independent third-party testing, inspection, and certification organization, has entered...

Company Deals

Burning Rock Expands Companion Diagnostics Partnership with Bayer for Precision Oncology in China

Fineline Cube May 31, 2024

Burning Rock Ltd (NASDAQ: BNR), a China-based medical technology company, has announced another partnership in...

Company Deals

Parexel Partners with Ruijin Hospital Hainan Subsidiary to Enhance Real-World Evidence in Drug Development

Fineline Cube May 31, 2024

Parexel, a U.S.-based contract research organization (CRO), has entered into a partnership with Shanghai Ruijin...

Company Drug

Hengrui Pharmaceuticals Advances Two Drug Candidates Following NMPA Clinical Trial Green Lights

Fineline Cube May 31, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Drug

JW Therapeutics Presents Positive Clinical Data for Carteyva in SLE at EULAR 2024

Fineline Cube May 31, 2024

JW Therapeutics (HKG: 2126), a biopharmaceutical company based in China, has presented new clinical data...

Company Drug

Akeso Inc.’s Ivonescimab Shows Positive Interim Analysis in Phase III NSCLC Study

Fineline Cube May 31, 2024

Akeso Inc. (HKG: 9926), a biopharmaceutical company based in China, has announced positive interim analysis...

Company Deals

Lucy Therapeutics Boosts CNS Disease Research with USD 12.5 Million in Additional Financing

Fineline Cube May 31, 2024

Lucy Therapeutics Inc., a U.S.-based developer of small-molecule drugs for central nervous system (CNS) diseases,...

Company Drug

Laekna Therapeutics Initiates Phase III Trial for Breast Cancer Candidate LAE002 in Combination with Fulvestrant

Fineline Cube May 30, 2024

Laekna Therapeutics Shanghai Co., Ltd, a biopharmaceutical company based in China, has announced the enrollment...

Company

Merck KGaA Launches Construction on Largest Asia-Pacific Investment with South Korean Bioprocessing Plant

Fineline Cube May 30, 2024

Merck KGaA (ETR: MRK), the German science and technology company, has commenced construction on a...

R&D

Shanghai Research Team Achieves Global First in Treating Type 2 Diabetes with Stem Cell Therapy

Fineline Cube May 30, 2024

A groundbreaking study out of Shanghai has made a significant stride in diabetes treatment. A...

Company Deals

Johnson & Johnson to Acquire Atopic Dermatitis Therapy NM26 in $1.25 Billion Deal

Fineline Cube May 30, 2024

Johnson & Johnson (J&J; NYSE: JNJ), a global healthcare giant, has entered into a definitive...

Company Drug

Jiangsu QYuns Therapeutics Initiates Phase III Trial for Skin Disease Candidate QX005N

Fineline Cube May 30, 2024

Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509), a biopharmaceutical company based in China, has announced...

Company Deals

HuidaGene and Synthego Form Strategic Partnership for CRISPR-Based Therapies

Fineline Cube May 30, 2024

HuidaGene (Shanghai) Biotechnology Co., Ltd, a clinical-stage biotechnology company based in China, has entered into...

Company Drug

Wanbangde’s Huperzine A Earns Orphan Drug Status from FDA for Treating Neonatal Brain Injury

Fineline Cube May 30, 2024

Wanbangde New Building Materials Co., Ltd (SHE: 002082), a company operating in China, has announced...

Company Drug

Zelgen Biopharmaceuticals Gets NMPA Approval for Jacktinib Vitiligo Trial in Adolescents and Adults

Fineline Cube May 30, 2024

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has received...

Company Drug

Hengrui Pharmaceuticals’ Vitiligo Treatment SHR0302 and Diabetes Drug HRS9531 Get Green Light from China’s NMPA

Fineline Cube May 30, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading biopharmaceutical company based in China, has...

Company Deals

Fosun Pharma Rumored to Fully Acquire Subsidiary Henlius Pharmaceutical, Shares Suspended

Fineline Cube May 30, 2024

Rumors are circulating, as reported by Bloomberg citing insiders, that Shanghai Fosun Pharmaceutical (Group) Co.,...

Company Drug

Amgen’s Bkemv Becomes First Biosimilar to Challenge AstraZeneca’s Soliris with FDA Approval

Fineline Cube May 30, 2024

Amgen Inc. (NASDAQ: AMGN), a leading biopharmaceutical company, has been granted regulatory approval by the...

Company Drug

Full-Life Technologies Receives FDA Green Light for ²²⁵Ac-FL-020 Clinical Study in mCRPC

Fineline Cube May 30, 2024

Full-Life Technologies Ltd, a globally integrated radiotherapeutics company with a presence in Belgium, Germany, and...

Company Deals Medical Device

Jiangxi Rimag Group Sets IPO Price Range for Hong Kong Debut, Aims to Raise Up to USD 2.15 per Share

Fineline Cube May 30, 2024

Jiangxi Rimag Group Co., Ltd, a leading medical imaging services provider based in China, has...

Posts pagination

1 … 382 383 384 … 696

Recent updates

  • InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor
  • Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B
  • Boehringer Ingelheim Reports 16.2% H1 2026 Sales Growth Driven by JARDIANCE and New Oncology Launches
  • China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline
  • Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for HBM7575/SKB575, Long-Acting Bispecific Antibody for Asthma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor

Company Drug

Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B

Company

Boehringer Ingelheim Reports 16.2% H1 2026 Sales Growth Driven by JARDIANCE and New Oncology Launches

Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.